Today we will delve into the contentious issue of vaccines in the food supply.

Accurate information on this topic is not easy to find. The USDA and drug developers aren't required to release any information on veterinary drugs in the development pipeline, so independent detectives are left searching through peer-reviewed papers, university publications, USDA contracts, grant notifications, company white papers, and university websites to learn what is on the horizon. This system is far from transparent, and frankly, I don't think that's an accident.

Before any vaccine technology is used on humans, it is usually tried in the veterinary market first due to the incredibly lax regulations. Knowing this, it should come as no surprise that our food animals had been receiving mRNA injections for years before the Covid vaccine rollout.

Around 2014, the USDA granted a conditional license for an mRNA vaccine for use in pigs for Porcine Epidemic Diarrhea Virus. This is equivalent to emergency use authorization and gets around the USDA's vaccine licensing and authorization process.

In 2015, Merck bought Harrisvaccines to acquire their RNA platform. Merck's 2015 press release stated that this "RNA Particle technology…represents a breakthrough in vaccine development. It also has a highly versatile production platform able to target a wide range of viruses and bacteria. Pathogens are collected from a farm, and specific genes are sequenced and inserted into RNA particles, making safe, potent vaccines able to provide herd-specific protection."

Introduced in 2018, Sequivity is Merck's RNA vaccine platform built on the Harrisvaccines technology. These RNA injections are already in use in pigs. They are customized for different viruses, and each customized injection undergoes no new safety testing; new formulations are deployed immediately. Pork you are eating from the supermarket is already likely treated with these gene therapies.